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The number of people living with disabilities worldwide is rapidly growing due to a longer 
life expectancy and the subsequent increasing burden of chronic diseases. The need of 
developing and implementing effective strategies aimed at delaying or preventing disabil-
ity has been repeatedly underlined and is currently the main focus of several health-care 
policies. In this scenario, a special attention is addressed to the identification of specific 
clinical conditions measuring the risk profile of the individual of developing an overt dis-
ability and other negative outcomes. These risk profiles can indeed become promising 
targets for developing and implementing preventive interventions. When the disabling 
cascade is fully established, in fact, the reversing/attenuating the process becomes 
more challenging. However, the exact nature of these relatively new constructs is not yet 
sufficiently clear, and several related issues remain poorly explored. In particular, these 
entities tend to be considered as unequivocally prodromal stages of a future disease, 
neglecting and underestimating their fluctuations/transitions over time and their potential 
to clinically improve/revert. This unbalanced judgment did probably contribute to an 
ambiguous and biased use of these conditions. Considering them as an early stage of an 
unavoidable future disease, in fact, determined a tendency to start a targeted interven-
tion as if in presence of the disease itself, with the subsequent risk of over-diagnosis and 
over-treatment. In the present article, we discuss the dynamics underlying the reversion 
from a clinical at-risk condition to normality and its implications, specifically focusing on 
the examples of frailty and mild cognitive impairment.
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inTRODUCTiOn
Populations are rapidly aging worldwide as result of a longer life expectancy (1). Such progressive 
increase in longevity is the sign of major scientific and societal accomplishments (2). However, the 
longer life expectancy is associated with an increased prevalence of chronic diseases and disabling 
conditions (3). The number of people living with some form of disability is, in fact, globally growing (4). 
In this scenario, the identification and implementation of effective strategies aimed at delaying or 
preventing disability is the main focus of many health-care policies (1, 5).
FigURe 1 | Trajectories of cognitive functioning and potential outcomes of mild cognitive impairment (MCI) in the so-called “dementia continuum.”
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The early identification and targeting of specific clinical pro-
files that could potentially serve as targets for preventive actions 
against disabilities and other negative outcomes has, reasonably 
and not surprisingly, focused the interest of both research and 
public health. In fact, once any disabling condition is fully 
established, the possibilities of functional improvement result 
drastically reduced.
Several clinical conditions measuring the risk profile of the indi-
vidual have recently been proposed in different fields of research. 
Some of these are also gradually acquiring some relevance in the 
clinical setting (6–9). However, a number of aspects related to 
these constructs still do not focus enough attention, thus risking 
to remain poorly explored, to cause misunderstandings, and to be 
the target of disputable interventions. In particular, these entities 
are frequently considered as prodromal stages, within a unidi-
rectional pathway toward subsequent disabilities. This approach 
mistakenly overlooks the possible fluctuations/transitions of 
the risk profile over time, and do not adequately consider the 
potential for spontaneous clinical improvement/remission. Such 
“inverse” trajectories, though commonly observed in routine 
clinical practice, are often underestimated, thus leading to unbal-
anced and biased consideration of these conditions.
In the present review, we present and discuss available evidence 
on the spontaneous reversion to normality from two of the most 
frequently studied and adopted at-risk conditions, namely frailty 
and mild cognitive impairment (MCI). Although they have been 
differently conceived and refer to different functions/domains 
of the individual, both these constructs have been developed in 
order to capture and measure the risk of developing poor health-
related outcomes. This parallelism allows to address some of the 
issues potentially arising from such “anticipatory” approach to 
disabling conditions (i.e., disability and dementia in these cases).
Reversion of MCi
Mild cognitive impairment is defined as an objective impairment 
of cognitive abilities that does not affect the subject’s functional 
independence (9). It is often considered as an intermediate 
stage in the progression from normal cognitive functioning to 
dementia (10). To date, the scientific and clinical interest on this 
construct has mostly been due to its being a condition increasing 
the risk of developing overt dementia. Subjects with MCI, in fact, 
show an annual rate of progression to dementia ranging from 5 
to 15%, depending on the setting and the considered operational 
definitions (11). Within this framework, MCI may be considered 
as a promising clinical condition to identify early signs of a pos-
sible progression to dementia and thus design ad hoc preventive 
interventions.
However, MCI does not necessarily convert to dementia, but 
can potentially follow other trajectories over time (12) (Figure 1). 
The majority of subjects with MCI does not experience a worsen-
ing of cognition over time, but tends to remain clinically stable. 
Population-based studies have actually shown that “stability” 
might be the most common pattern after a diagnosis of MCI, 
occurring in 37–67% of the overall cases (12). The limited length 
of follow-up adopted by available studies on the topic, however, 
does not allow to draw conclusions on the actual length of this 
plateau. Anyway, an adequate description of MCI should not 
omit considering the absence of a conversion to cognitive decline. 
Moreover, an increasing number of longitudinal data show that 
a relevant proportion of subjects with MCI may even revert to 
normal cognition. Two systematic reviews and meta-analyses 
have recently been carried out to estimate the rate of “reversion” 
from MCI to normality (13, 14). A first review considered 25 lon-
gitudinal studies (published from 1999–2015) enrolling subjects 
with MCI with a follow-up equal or longer than 2 years (13). An 
overall 18% (95%CI 14–22%) reversion rate from MCI to normal 
cognition was observed. In particular, estimates significantly 
varied according to study setting, with an 8% (95%CI 4–11%) 
reversion rate in clinical-based studies, and a 25% (95%CI 
19–30%) rate in population-based ones. When considering only 
studies meeting higher quality standards (reported in Table 1), 
the frequency of reversion further increased to 26%. Consistently, 
Table 1 | Characteristics of available observational studies meeting high quality standards addressing the spontaneous reversion of mild cognitive impairment (MCI).
Reference Setting n Sex (%F) Mean age Follow-up (years) MCi definition Reversion (%)
Grande et al. (15) C 374 60.2 75.1 ± 6.9 2.7 ± 2.1 IWG 5.6
Roberts et al. (16) P 534 44.6 na 5.1 IWG 37.6
Sachdev et al. (17) P 320 51.1 11.5 ± 0.8a 1.9 ± 0.1 IWG 20.6
Manly et al. (18) P 564 68.0 76.5 ± 1.3a 5 Mayo Clinic 30.1
Pérès et al. (19) P 285 57.2 na 2 Mayo Clinic 21.4
Larrieu et al. (20) P 58 na na 2 Mayo Clinic 41.4
Modified from Ref. (13).
C, clinical-based study; P, population-based study; na, not available; IWG, International Working Group criteria for MCI; Mayo, Mayo Clinic criteria for MCI.
aWeighted mean values.
In the present table, we report the six studies of “better quality,” defined using the Quality in Prognostic Studies tool (21), included in a previous meta-analysis on the topic (13).
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high rates of reversion (31% in the community setting and 14% in 
the clinical setting) were also documented by a second systematic 
review, which did not apply restrictions based on the length of 
follow-up, and only included studies adopting the Mayo Clinic 
criteria to define amnestic MCI (14).
Despite such high rates of reversion, research on the identifi-
cation of potential factors associated with a favorable trajectory 
of MCI is still lacking. Evidence from the few available studies 
indicates that genetic traits (i.e., absence of APOE ε4 alleles), soci-
odemographic factors (i.e., younger age and higher educational 
level), clinical features (i.e., greater degree of non-neurological 
comorbidities), functional independence (i.e., better scores on 
functional tests), the subtype of MCI (i.e., single-domain non-
amnesic), the global cognitive performance (i.e., higher scores 
at the cognitive tests), and neuroimaging findings (i.e., larger 
hippocampal volumes) may positively influence the probability 
of reversion (12, 15, 17, 22).
Another aspect in this field that has not yet been adequately 
explored is the cognitive stability of subjects reverting from MCI 
to a normal cognitive function. In the Pittsburgh Cardiovascular 
Health Study-Cognition Study, a relevant heterogeneity was 
observed in the clinical course of “reverters.” Some of the par-
ticipants remained stable within the normal cognition range, but 
other reconverted to MCI or even progressed to dementia (23). 
Consistently, another study found that subjects with MCI who 
reverted to normal cognition were still at an increased risk of 
developing dementia later in time when compared to cognitively 
normal subjects (16).
An additional point that needs to be further investigated 
is whether the adoption of biomarkers reflecting in  vivo the 
occurrence of neuropathological modifications may improve 
the differentiation of the heterogeneous MCI trajectories. Some 
specific biomarkers might possibly support a better discrimi-
nation of MCI cases and help identifying those with a higher 
probability of progressing to dementia or reverting to normal 
cognition. Research, however, has been primarily focused on 
identifying biomarkers associated with a negative outcome (i.e., 
progression to dementia), largely ignoring those potentially pre-
dicting a reversion to normality. It is very likely that these latter 
cannot be exhaustively found in pathophysiological mechanisms 
responsible for the onset of the disease, but they may worth the 
opening of a novel axe of research. In fact, there are reports of 
clinical reversion to normality among subjects with MCI clearly 
exhibiting the traditional neuropathological abnormalities (i.e., 
amyloid deposition) suggestive of an underlying neurodegen-
eration (24).
Reversion of Frailty
Frailty is defined as “a medical syndrome with multiple causes 
and contributors that is characterized by diminished strength, 
endurance, and reduced physiologic function that increases an 
individual’s vulnerability for developing increased dependency 
and/or death” (5). It is also considered as a marker of biological 
aging and increasingly indicated as a condition of public health 
interest (25).
To date, frailty has frequently been approached as a pre-disa-
bility state (26) and as a condition increasing the risk of adverse 
health-related outcomes (e.g., falls, functional loss, hospitaliza-
tion, institutionalization, death) in the elderly (6). Similarly to 
MCI, much of the interest toward this construct has been due to 
its ability to predict subsequent negative events. Several studies, 
however, have proven the dynamic nature of frailty, with frail 
individuals either worsening or improving over time and show-
ing multiple and bidirectional health “transitions” (6). Again, the 
potential of frailty for spontaneous clinical remission has, to date, 
been rarely investigated.
The group of observational studies that have, so far, addressed 
the spontaneous reversion of frailty are described in Table  2 
(27–33). Only articles published on PubMed, from inception 
to July 2017, or retrieved from the bibliographies of pertaining 
studies were considered for the present purposes. Available 
evidence mostly comes from population-based studies enrolling 
representative samples of community-dwelling older people, 
with sample sizes ranging from 122 (29) to 15,776 (31) par-
ticipants, and time spans of observation varying from 1 (29) to 
6.4 years (32). One study specifically investigated the transitions 
of frailty among subjects with cognitive disorders (29). All the 
studies defined frailty using modified versions of the phenotype 
proposed by Fried and colleagues (34), which differentiates the 
specific conditions of robustness, pre-frailty, and frailty. Relevant 
rates of spontaneous reversion were observed across the available 
studies, with 13.8 (33) to 44.6% (30) of frail participants reverting 
to pre-frailty or robustness. One study estimated the possibility 
of reversion over time using data from three follow-up visits (33). 
It documented a time-dependent reduction in the probability of 
favorable transitions. In the overwhelming majority of cases, the 
most common positive trajectory was toward a pre-frail status 
rather than to robustness.
Table 2 | Characteristics of available observational studies addressing the spontaneous reversion of frailty.
Reference Setting n Sex (%F) Mean age Follow-up (years) Frailty  
prevalence (%)
Frailty 
definition
Reversion (%)
Trevisan et al. (27) P 3,099 59.7 74.4 ± 7.3 4.4 7.6 mFP 28.2
Jamsen et al. (28) P 1,705 0.0 76 (median) 2 Na mFP Overall transitions to prefailty/
robustness: 17.41,366 0.0 78 (median) 2–5 Na
Chong et al. (29) C 122 59.4 75.4 ± 7.2 1.0 41.0 mFP 32.0
Lee et al. (30) P 3,427 43.7 74.0 ± 1.6a 2.0 7.9 mFP 44.6
Borrat-Besson et al. (31) P 15,776 na na 4.0 6.1 mFP 38.9
Espinoza et al. (32) P 597 55.1 69.6 ± 3.4 6.4 9.3 mFP 28.8
Gill et al. (33) P 754 64.6 78.4 ± 5.3 1.5 25.7 mFP 23.0
679 65.1 79.7 ± 5.2 1.5–3 31.8 17.9
626 66.3 81.0 ± 5.1 3–4.5 36.7 13.8
C, clinical-based study; P, population-based study; mFP, modified Frailty Phenotype; na, not available.
aWeighted mean values.
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Research on the factors associated to or predicting a sponta-
neous reversion from frailty are still inconclusive. Results from 
available studies on possible sex differences are conflicting. Some 
studies, in fact, reported higher reversion rates among women 
(27, 30), other studies failed to show any significant association 
between gender and reversion rates, and one study reported 
that men were more likely to improve (31). Other determinants 
that were studied as possible predictors of reversion from frailty 
are younger age (only in women), higher educational levels, 
living alone, low-to-moderate alcohol consumption, being 
overweight, and practicing regular physical activity (27, 30, 31). 
One study found no association between the overall number 
of medications and burden of anticholinergic drugs, and the 
progression/regression from frailty over time (28). As for MCI, 
no consistent data are available describing the long-term trajec-
tories of frail subjects having experienced a spontaneous clinical 
improvement.
DiSCUSSiOn
Considering available evidence, reversion should be seen as a 
quite common outcome of clinical conditions measuring the risk 
profile of the individual such as MCI and frailty. Knowing that 
these at-risk profiles have the potential to spontaneously regress, 
a more balanced and cautious attitude should be adopted when 
approaching these entities both in clinical and in research settings.
Widening the knowledge on the phenomenon of reversion, 
within the preventive management of disabling conditions, may 
have important practical implications. The possibility of identify-
ing those subjects that are more likely to show a positive outcome, 
in fact, may allow to better allocate health-care resources in the 
heterogeneous population of aging individuals (35). Moreover, 
it may prevent possible negative consequences arising from the 
(mis)diagnosis of a potentially disabling conditions (e.g., dis-
crimination, stigmatization, over-medicalization) (13). Finally, it 
may improve the design of clinical trials and the interpretation 
of their results. For example, excluding subjects whose cognitive 
function or frailty levels are unlikely to decline over time may 
increase the effect size of potentially effective interventions. As of 
today, this point seems of crucial interest, considering that nearly 
180 RCTs are currently recruiting subjects with frailty and/or 
MCI worldwide (source: www.clinicaltrials.gov; search updated 
in August 2017).
Several hypotheses may be proposed to explain the observed 
remission of the considered at-risk conditions (13). First, it may 
simply be due to the wrong classification of subjects participat-
ing in the studies, with either normal individuals misdiagnosed 
as frail/MCI at enrollment, or with frail/MCI subjects misclas-
sified as normal at the end of the observation period. According 
to this hypothesis, the spontaneous remission of the considered 
conditions might be explained by the weakness of the adopted 
definitions and diagnostic tools adopted. At the same time, the 
intrinsic tendency of these entities—that define a risk and not 
a nosological condition—to fluctuate over time and exhibit 
unstable courses cannot be ignored. This aspect is strongly 
related to the multiple factors (e.g., nutritional deficits, affec-
tive disorders, cerebrovascular events, sleep disorders, social 
issues) that can be at the basis of their clinical manifestations. 
Thus, among the large number of individuals at risk (due to 
frailty or MCI), there will undoubtedly be a subgroup with the 
features leading to unavoidable further decline, but there will 
also be a group, labeled as having a “positive” risk profile, who 
will not necessarily follow a negative trajectory, and is simply 
categorized as at risk due to a temporary/reversible condition 
and/or to a mistake in the evaluation process. The correct 
definition of these aspects is extremely relevant in terms of 
public health. The current trend is to extend the boundaries of 
clinical interventions to at-risk conditions, without adequately 
considering the possibility of spontaneous reversion, and this 
is unsustainable in terms of a health economics, because it 
exponentially increases the number of “individuals to treat.”
Overall, these considerations underline the limits arising 
from attempting to approach age-related disabling conditions 
using the traditional medical approach based on a stand-alone 
disease model. The prevention of clinical conditions cannot 
meet the same standards and follow the methodologies applied 
in the treatment of diseases. Defining new conditions to treat 
does not mean carrying out effective preventive actions. The 
prevention of age-related conditions requires the adoption of 
a more naturalistic approach to older subjects, thus should be 
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focused on identifying the trajectories of their functions rather 
than on a punctual assessment of (arbitrary and categorical) 
entities. The complexity of health conditions in older age and of 
age-related disorders might be better approached by adopting 
measures reflecting the trajectories of personal capacities and 
abilities, and identifying the interaction between the intrinsic 
characteristics of each subject and his/her environment (1). This 
model may better support the personalization of care and the 
implementation of person-tailored interventions. Special atten-
tion should also be devoted to those events or variables that may 
constitute “switching factors” along the individual’s trajectories, 
thus positively or negatively modifying the direction of func-
tional and clinical changes over time.
In conclusion, considering their unstable and potentially 
bidirectional course, MCI, frailty and other similar risk profiles 
associated with disabling conditions should not be framed into 
nosological conditions nor considered as prodromal phases 
of an unavoidable subsequent disease. They should be more 
adequately approached as the heterogeneous at-risk condi-
tions they were originally designed to be. Such more balanced 
perspective will allow to reduce the risk of over-diagnosis 
and over-treatment, and to improve the clinical and research 
standards in this field. Moreover, the progressive adoption of 
longitudinal constructs that are more precise at reflecting the 
complex functioning of aging people and at overcoming the 
weaknesses of traditional categorical frameworks should be 
promoted.
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